Vanguard reports 5.21% stake in Cytokinetics
Cytokinetics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,422,042 shares of Cytokinetics common stock, constituting 5.21% of the class as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cytokinetics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,422,042 shares of Cytokinetics common stock, constituting 5.21% of the class as of 03/31/2026. The filing lists sole voting power of 933,408 shares and sole dispositive power over all reported shares.
Insights
Vanguard holds a >5% passive stake in Cytokinetics.
Vanguard Capital Management reported beneficial ownership of 5.21% as of 03/31/2026, with 6,422,042 shares and sole dispositive power over those shares. The filing is a routine Schedule 13G disclosure for an institutional investor.
Implications are neutral: the stake signals institutional interest but the filing does not indicate an activist intent or a change in control. Subsequent filings could show changes in voting arrangements or percent ownership.
Key Figures
Key Terms
Schedule 13G regulatory
Sole dispositive power financial
Beneficial ownership regulatory
Investment Company Act of 1940 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard hold in Cytokinetics (CYTK)?
What does sole dispositive power mean in the CYTK filing?
Is Vanguard an activist investor in Cytokinetics based on this filing?
Who signed the Schedule 13G for Vanguard in the CYTK filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.